Finance
Juvaris announces first round closing of series A financing
Published in Health Business Week, February 9th, 2007
The second closing will occur within 120 days from the date of the first closing, bringing the total series A round to $12 million.
The funds will enable the company to advance its lead vaccine products for influenza and pneumonia indications to clinical trials. The company will also pursue immunotherapy products for hepatitis B and biodefense applications. The funds permitted the company to close asset purchase agreements negotiated with...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
Source: Health Business Week (2007-02-09)
More Articles from Health Business Week
- Accreditation
Vested Health health plan receives URAC consumer education and support accreditation - Acid Suppression
Study finds first-day acid suppression similar in two top-selling OTC heartburn treatments - Acute Myeloid Leukemia
Xanthus receives orphan drug designation of Xanafide for treating acute myeloid leukemia - Acute Radiation Syndrome
U.S. FDA clears Humanetics' IND filing to commence clinical studies on new radiation countermeasure - Addiction Medicine
Stanford study will test antidepressant patch that may help smokers kick the habit - Addiction Medicine
Study results on memory's link to recovering from addiction published in Harvard newsletter - More from this issue of Health Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
